从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三人年薪分别为284万元、171.11万元、136.67 万元。 从薪酬变动幅度看（仅统计任职两年以上董秘薪资数据），迪瑞医疗的安国柱2024年薪酬降幅最大，同比降幅达25.82%；九强生物的王建民薪酬增幅最大，同比涨幅达172.86%。 责任编辑：公司观察 专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达4 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除董秘已离任公司后，A股共有35家上市体外诊断公司，其聘任总体情 况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到69%；50岁以上的董秘占比 为11%；40岁及以下董秘群体占比为20%。其中，目前仍任职的最年轻的男上市公司董秘年龄33岁，为 爱威科技的袁绘杰；最年轻的女董秘年龄为32岁，为易瑞生物的李文天。 从董秘的学历分布看，拥有本科、硕士学历的董秘占比分别为40%、60%。 从薪酬分布看，A股体外诊断公司董秘年薪平均值为77万元。经统计，处于50万以下、50万-100万、 100万-200万、200万以上各区间的人数占比分别为20%、63%、14%、3%。 其中，年薪排行前三的董秘分别为新产业的张蕾、科华生物的金红英、硕世生物的胡园园，三 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, particularly its low PE ratio compared to industry averages [1][2] - As of August 7, Aiwei Technology's stock closed at 27.02 yuan, with a PE ratio of 76.27, marking a new low in 832 days and a total market capitalization of 1.837 billion yuan [1] - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Aiwei Technology at 96th place within the industry [1][2] Group 2 - For Q1 2025, Aiwei Technology reported revenue of 53.2953 million yuan, reflecting a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's gross profit margin stands at 55.59%, indicating a strong profitability relative to its revenue [2] - As of March 31, 2025, Aiwei Technology had 3,605 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, particularly its low PE ratio compared to industry averages [1][2] - As of August 4, Aiwei Technology's stock closed at 26.19 yuan, with a PE ratio of 73.93, marking a new low in 819 days and a total market capitalization of 1.781 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 54.32 and a median of 38.11, placing Aiwei Technology at the 93rd position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Aiwei Technology reported revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% [2] - The company's gross profit margin stands at 55.59%, indicating a strong profitability relative to its revenue [2] - As of March 31, 2025, Aiwei Technology had 3,605 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

爱威科技8月4日大宗交易平台出现一笔成交，成交量12.30万股，成交金额307.62万元，大宗交易成交价 为25.01元，相对今日收盘价折价4.51%。该笔交易的买方营业部为国海证券股份有限公司山东分公司， 卖方营业部为国联民生证券股份有限公司北京建材城西路证券营业部。 进一步统计，近3个月内该股累计发生4笔大宗交易，合计成交金额为1125.58万元。 证券时报·数据宝统计显示，爱威科技今日收盘价为26.19元，上涨3.60%，日换手率为2.95%，成交额为 5095.53万元，全天主力资金净流入309.61万元，近5日该股累计上涨4.34%，近5日资金合计净流入 286.89万元。 两融数据显示，该股最新融资余额为4682.49万元，近5日增加262.66万元，增幅为5.94%。（数据宝） 8月4日爱威科技大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 12.30 | ...

Group 1 - The core transaction of Awei Technology involved 123,000 shares traded on August 4, with a total transaction value of 3.0762 million yuan, accounting for 5.69% of the total trading volume for that day [1][2] - The transaction price was 25.01 yuan, which represents a discount of 4.51% compared to the market closing price of 26.19 yuan [1][2]

7月30日，爱威科技今日收盘24.3元，下跌1.22%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到68.59倍，总市值16.52亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入5329.53万元，同比13.85%；净利润632.10万 元，同比24.63%，销售毛利率55.59%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13爱威科技68.5972.343.2916.52亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿1九安医疗11.0711.200.87186.87亿2英科医疗 14.0715.171.25222.33亿3新华医疗15.9114.751.30101.98亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2116.261.86153.29亿6奥美医疗16.3215.991.6858.96亿7康德莱17.1917.201.4237.04亿8九强生物 17.5016.272.1486.66亿9奥泰生物17.8318.801.4456.87亿10维力医疗18.4919.222.264 ...

Group 1 - The core point of the article highlights a significant block trade involving Aiwei Technology on July 29, with a transaction volume of 130,000 shares and a transaction amount of 3.0537 million yuan, executed at a price of 23.49 yuan, which represents a discount of 4.51% compared to the closing price of the day [2] - In the last three months, Aiwei Technology has recorded a total of three block trades, with a cumulative transaction amount of 8.1796 million yuan [2] - The closing price of Aiwei Technology on the day of the report was 24.60 yuan, reflecting a decline of 1.99%, with a daily turnover rate of 2.64% and a total transaction amount of 44.1371 million yuan [2] Group 2 - The net inflow of main funds for Aiwei Technology on that day was 3.1483 million yuan, and over the past five days, the stock has increased by 2.41% with a total net inflow of 2.0845 million yuan [2] - The latest margin financing balance for Aiwei Technology is 46.1981 million yuan, which has increased by 5.18 million yuan over the past five days, representing a growth rate of 12.63% [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aiwei Technology, which operates in the medical device industry, showing a high PE ratio compared to industry averages [1][2] - As of July 29, Aiwei Technology's closing price was 24.6 yuan, with a PE ratio of 69.44, significantly higher than the industry average of 55.46 and the median of 37.74 [1][2] - The company's total market capitalization is 1.673 billion yuan, ranking it 92nd in the industry based on PE ratio [1][2] Group 2 - For Q1 2025, Aiwei Technology reported revenue of 53.2953 million yuan, a year-on-year increase of 13.85%, and a net profit of 6.3210 million yuan, up 24.63% year-on-year, with a gross margin of 55.59% [1] - The company holds 259 authorized patents, including 97 domestic invention patents and 18 overseas patents, along with 30 software copyrights [1] - Aiwei Technology specializes in the research, production, sales, and service of medical clinical testing analysis instruments and related in vitro diagnostic reagents and medical consumables [1]

Group 1 - On July 29, Awei Technology executed a block trade of 130,000 shares, with a transaction amount of 3.0537 million yuan, accounting for 6.47% of the total trading volume for the day [1] - The transaction price was 23.49 yuan, which represents a discount of 4.51% compared to the market closing price of 24.6 yuan [1]